Developing a vaccine to protect against tularemia
Official title: Translation of a highly protective tularemia vaccine to the NHP model
Funded at Albany Medical College · NIH-11010869 · Data updated 2026-11-12
This study is working on a new vaccine to help protect people from tularemia, a serious illness caused by a germ, and it's testing how well these vaccines work in animals to find the best options for future human trials.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Albany Medical College NIH-funded |
| Lab location | 1 site (Albany, United States) |
| Project start | January 15, 2024 |
| Project end | November 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $787,600 |
| NIH project number | 5R01AI179706-02 |
| Project ID | NIH-11010869 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research would include individuals at high risk of exposure to tularemia, such as healthcare workers or those in endemic areas.
✕Less likely to help
Patients who are not at risk of tularemia exposure or those with existing immunity to the disease may not benefit from this research.
What this research studies
This research focuses on creating a vaccine for tularemia, a severe disease caused by the bacterium Francisella tularensis. The team is investigating vaccine candidates that can provide protection against high doses of the pathogen, particularly through aerosol exposure. By using animal models that closely mimic human responses, the researchers aim to identify effective vaccines and their correlates of protection, which are crucial for guiding future clinical trials. The study builds on past findings and seeks to advance vaccine development to better protect against this lethal infection.
Why it matters
Potential benefit: If successful, this research could lead to a highly effective vaccine that protects against tularemia, potentially saving lives and improving public health.
How similar studies have gone: Previous research has shown promise in developing vaccines for tularemia, but this approach aims to address unmet needs with more relevant animal models.
Where this research is happening
-
Albany Medical College
Albany, United States Active
Researchers
- Principal investigator: Hazlett, Karsten R.o. — Albany Medical College
- Study coordinator: Hazlett, Karsten R.o.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.